These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

547 related articles for article (PubMed ID: 34001239)

  • 1. Methylated circulating tumor DNA as a biomarker for colorectal cancer diagnosis, prognosis, and prediction.
    Nassar FJ; Msheik ZS; Nasr RR; Temraz SN
    Clin Epigenetics; 2021 May; 13(1):111. PubMed ID: 34001239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell-Free DNA as a Diagnostic Blood-Based Biomarker for Colorectal Cancer: A Systematic Review.
    Petit J; Carroll G; Gould T; Pockney P; Dun M; Scott RJ
    J Surg Res; 2019 Apr; 236():184-197. PubMed ID: 30694754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction, and screening for colorectal cancer.
    Luo H; Zhao Q; Wei W; Zheng L; Yi S; Li G; Wang W; Sheng H; Pu H; Mo H; Zuo Z; Liu Z; Li C; Xie C; Zeng Z; Li W; Hao X; Liu Y; Cao S; Liu W; Gibson S; Zhang K; Xu G; Xu RH
    Sci Transl Med; 2020 Jan; 12(524):. PubMed ID: 31894106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating tumor DNA is a prognostic marker of tumor recurrence in stage II and III colorectal cancer: multicentric, prospective cohort study (ALGECOLS).
    Benhaim L; Bouché O; Normand C; Didelot A; Mulot C; Le Corre D; Garrigou S; Djadi-Prat J; Wang-Renault SF; Perez-Toralla K; Pekin D; Poulet G; Landi B; Taieb J; Selvy M; Emile JF; Lecomte T; Blons H; Chatellier G; Link DR; Taly V; Laurent-Puig P
    Eur J Cancer; 2021 Dec; 159():24-33. PubMed ID: 34731746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between post-surgery detection of methylated circulating tumor DNA with risk of residual disease and recurrence-free survival.
    Murray DH; Symonds EL; Young GP; Byrne S; Rabbitt P; Roy A; Cornthwaite K; Karapetis CS; Pedersen SK
    J Cancer Res Clin Oncol; 2018 Sep; 144(9):1741-1750. PubMed ID: 29992492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating-tumour DNA methylation of HAND1 gene: a promising biomarker in early detection of colorectal cancer.
    Shavali M; Moradi A; Tahmaseb M; Mohammadian K; Ganji SM
    BMC Med Genomics; 2024 Apr; 17(1):117. PubMed ID: 38689296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of Circulating Tumor DNA Methylation in Diagnosis of Colorectal Cancer.
    Xu F; Yu S; Han J; Zong M; Tan Q; Zeng X; Fan L
    Clin Transl Gastroenterol; 2021 Aug; 12(8):e00386. PubMed ID: 34382948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating epigenetic biomarkers for detection of recurrent colorectal cancer.
    Symonds EL; Pedersen SK; Murray D; Byrne SE; Roy A; Karapetis C; Hollington P; Rabbitt P; Jones FS; LaPointe L; Segelov E; Young GP
    Cancer; 2020 Apr; 126(7):1460-1469. PubMed ID: 31909823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced Performance of DNA Methylation Markers by Simultaneous Measurement of Sense and Antisense DNA Strands after Cytosine Conversion.
    Jensen SØ; Øgaard N; Nielsen HJ; Bramsen JB; Andersen CL
    Clin Chem; 2020 Jul; 66(7):925-933. PubMed ID: 32460325
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Laven-Law G; Kichenadasse G; Young GP; Symonds EL; Winter JM
    Biomarkers; 2024 Jun; 29(4):194-204. PubMed ID: 38644767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A higher ctDNA fraction decreases survival in regorafenib-treated metastatic colorectal cancer patients. Results from the regorafenib's liquid biopsy translational biomarker phase II pilot study.
    Unseld M; Belic J; Pierer K; Zhou Q; Moser T; Bauer R; Piringer G; Gerger A; Siebenhüner A; Speicher M; Heitzer E; Prager GW
    Int J Cancer; 2021 Mar; 148(6):1452-1461. PubMed ID: 32949150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating tumour DNA for monitoring colorectal cancer-a prospective cohort study to assess relationship to tissue methylation, cancer characteristics and surgical resection.
    Symonds EL; Pedersen SK; Murray DH; Jedi M; Byrne SE; Rabbitt P; Baker RT; Bastin D; Young GP
    Clin Epigenetics; 2018; 10():63. PubMed ID: 29796114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and validation of methylation signatures in blood-based circulating tumor cell-free DNA in early detection of colorectal carcinoma: a case-control study.
    Sui J; Wu X; Wang C; Wang G; Li C; Zhao J; Zhang Y; Xiang J; Xu Y; Nian W; Cao F; Yu G; Lou Z; Hao L; Liu L; Li B; Zhang Z; Cai S; Liu H; Lan P; Zhang W
    Clin Epigenetics; 2021 Feb; 13(1):26. PubMed ID: 33536049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review of Blood-Based Colorectal Cancer Screening: How Far Are Circulating Cell-Free DNA Methylation Markers From Clinical Implementation?
    Worm Ørntoft MB
    Clin Colorectal Cancer; 2018 Jun; 17(2):e415-e433. PubMed ID: 29678513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical application of liquid biopsy in colorectal cancer: detection, prediction, and treatment monitoring.
    Tao XY; Li QQ; Zeng Y
    Mol Cancer; 2024 Jul; 23(1):145. PubMed ID: 39014366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating Cell-Free DNA and Colorectal Cancer: A Systematic Review.
    Vymetalkova V; Cervena K; Bartu L; Vodicka P
    Int J Mol Sci; 2018 Oct; 19(11):. PubMed ID: 30373199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aberrant circulating tumor DNA methylation and exosomal microRNA biomarkers for early detection of colorectal cancer.
    Zhang X; Hou H; Jiang M; Zhang X
    Mol Biol Rep; 2023 Mar; 50(3):2743-2750. PubMed ID: 36583782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating Tumor DNA as a Biomarker for Outcomes Prediction in Colorectal Cancer Patients.
    Petrillo A; Salati M; Trapani D; Ghidini M
    Curr Drug Targets; 2021; 22(9):1010-1020. PubMed ID: 33155906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating tumor DNA methylation marker MYO1-G for diagnosis and monitoring of colorectal cancer.
    Lin WH; Xiao J; Ye ZY; Wei DL; Zhai XH; Xu RH; Zeng ZL; Luo HY
    Clin Epigenetics; 2021 Dec; 13(1):232. PubMed ID: 34961566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early Detection of Molecular Residual Disease and Risk Stratification for Stage I to III Colorectal Cancer via Circulating Tumor DNA Methylation.
    Mo S; Ye L; Wang D; Han L; Zhou S; Wang H; Dai W; Wang Y; Luo W; Wang R; Xu Y; Cai S; Liu R; Wang Z; Cai G
    JAMA Oncol; 2023 Jun; 9(6):770-778. PubMed ID: 37079312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.